CDX Stock Overview
Engages in the design, manufacture, and marketing of medical devices used in cardiovascular health management in the Americas, Europe, and the Asia Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
CardieX Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.11 |
| 52 Week High | AU$0.17 |
| 52 Week Low | AU$0.045 |
| Beta | 1.46 |
| 11 Month Change | 39.24% |
| 3 Month Change | 96.43% |
| 1 Year Change | n/a |
| 33 Year Change | -79.25% |
| 5 Year Change | -60.71% |
| Change since IPO | -98.43% |
Recent News & Updates
Shareholder Returns
| CDX | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | -26.7% | 0.5% | 1.5% |
| 1Y | n/a | 14.2% | 17.2% |
Return vs Industry: Insufficient data to determine how CDX performed against the Australian Medical Equipment industry.
Return vs Market: Insufficient data to determine how CDX performed against the Australian Market.
Price Volatility
| CDX volatility | |
|---|---|
| CDX Average Weekly Movement | 20.5% |
| Medical Equipment Industry Average Movement | 9.1% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 17.3% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: CDX's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: CDX's weekly volatility has increased from 14% to 20% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | n/a | Craig Cooper | cardiex.com |
CardieX Limited engages in the design, manufacture, and marketing of medical devices used in cardiovascular health management in the Americas, Europe, and the Asia Pacific. It offers SphygmoCor, a vascular biometric technology that captures central hemodynamics and arterial stiffness for noninvasive measurement of vascular biomarkers including central aortic pressures and arterial stiffness indices. The company also provides medical devices and vascular biomarkers for hypertension, cardiovascular disease, and other vascular health disorders; and develops and sells medical devices, digital solutions, and wearables, home health, decentralized clinical trials, and remote patient monitoring.
CardieX Limited Fundamentals Summary
| CDX fundamental statistics | |
|---|---|
| Market cap | AU$34.57m |
| Earnings (TTM) | -AU$6.77m |
| Revenue (TTM) | AU$12.81m |
2.5x
P/S Ratio-4.8x
P/E RatioIs CDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CDX income statement (TTM) | |
|---|---|
| Revenue | AU$12.81m |
| Cost of Revenue | AU$797.87k |
| Gross Profit | AU$12.02m |
| Other Expenses | AU$18.78m |
| Earnings | -AU$6.77m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.023 |
| Gross Margin | 93.77% |
| Net Profit Margin | -52.80% |
| Debt/Equity Ratio | 79.0% |
How did CDX perform over the long term?
See historical performance and comparison